Sign in →

Test ID SEQA Sequential Maternal Screening, Part 1, Serum


Advisory Information


When part 1 is negative, part 2 must be completed in order to receive an interpretable result. If collecting a second-trimester specimen is expected to be difficult, order first-trimester screening instead (see 1STT1 / First Trimester Maternal Screen, Serum).

 

If a stand-alone neural tube defect risk assessment is desired, order MAFP1 / Alpha-Fetoprotein (AFP), Single Marker Screen, Maternal, Serum.



Additional Testing Requirements


Sequential maternal screening is a 2-part test that includes a first-trimester sample (SEQA / Sequential Maternal Screening, Part 1, Serum) and a second-trimester sample (SEQB / Sequential Maternal Screening, Part 2, Serum).



Necessary Information


Approval to send specimen for first-trimester screening is required and may take up to 5 business days to complete. Nuchal translucency (NT) measurements are only accepted from NT-certified sonographers. Do not send specimen to Mayo Clinic Laboratories if the sonographer is not NT-certified or before completing the application process. See Maternal Screening: Sonographer Approval Process in Special Instructions. Complete the NT/CRL Data for First Trimester/Sequential Maternal Screening form in Special Instructions.



Specimen Required


Container/Tube: 

Preferred: Red top

Acceptable: Serum gel

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions:

1. The ultrasound and blood draw must be completed within a gestational window of 10 weeks, 0 days and 13 weeks, 6 days, which corresponds to a crown-rump length (CRL) range of 31 to 80 mm.

2. Centrifuge and aliquot serum within 2 hours of collection.


Forms

First Trimester/Sequential Maternal Screening Patient Information (T593) is required; see Special Instructions.

Useful For

First-trimester prenatal screening for Down syndrome (trisomy 21) and trisomy 18

Testing Algorithm

Sequential maternal screening is a 2-step test, with first- and second-trimester components. It requires a nuchal translucency (NT) measurement and blood collection in the first trimester. If the result from part 1 indicates a risk for Down syndrome that is higher than the screen cutoff, the screen is completed and a report is issued. If the results from part 1 are negative, an additional blood collection in the second trimester is required (see SEQB / Sequential Maternal Screening, Part 2, Serum). If the second specimen is not received for sequential screening, the results are uninterpretable and no maternal risk will be provided.

 

The following are available in Special Instructions:

-Sequential Maternal Serum Screening Testing Process

-Prenatal Aneuploidy Screening and Diagnostic Testing Options Algorithm

Method Name

Immunoenzymatic Assay

Reporting Name

Sequential Maternal Screen, Part 1

Specimen Type

Serum

Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 7 days
  Frozen  90 days

Reference Values

An interpretive report will be provided.

Day(s) and Time(s) Performed

Monday through Friday; 8 a.m.-4:30 p.m.

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

84163

LOINC Code Information

Test ID Test Order Name Order LOINC Value
SEQA Sequential Maternal Screen, Part 1 49086-2

 

Result ID Test Result Name Result LOINC Value
29451 Recalculated Maternal Serum Screen 43995-0
601802 Results Summary 50679-0
29469 Down Syndrome Screen Risk Estimate 43995-0
29470 Down Syndrome Maternal Age Risk 49090-4
29471 Trisomy 18 Screen Risk Estimate 43994-3
29468 PAPP-A 48407-1
601799 PAPP-A MoM 76348-2
NT1 NT 33069-6
601800 NT MoM 49035-9
NTTB1 NT Twin 33069-6
601801 NT Twin MoM 49035-9
29472 Interpretation 49586-1
29474 Recommended Follow Up 80615-8
29473 Additional Comments 48767-8
29452 Specimen Collection Date 33882-2
29453 Maternal Date of Birth 21112-8
29890 Calculated Age at EDD 43993-5
29454 Maternal Weight 29463-7
29455 Maternal Weight 29463-7
DIAB1 Insulin Dependent Diabetes 33248-6
RACE_ Patient Race 32624-9
SMKN2 Current cigarette smoking status 72166-2
SNDT1 Scan Date 34970-4
CRL1A CRL 11957-8
CRL2A CRL Twin 11957-8
29891 GA on Collection by U/S Scan 11888-5
FET1 Number of Fetuses 11878-6
CHOR1 Chorions 92568-5
IVF1 IVF 47224-1
PRHIX Prev Down (T21) / Trisomy Pregnancy 53826-4
PRNTA Prev Pregnancy w/ Neural Tube Defect 53827-2
PTNTA Patient or father of baby has a NTD 53827-2
INTL2 Initial or repeat testing 86955-2
SONOM Sonographer Name 49088-8
SNCD1 Sonographer Code No LOINC Needed
SONO1 Sonographer Reviewer ID 49089-6
DRPH2 Physician Phone Number 68340-9
29487 General Test Information 62364-5

NY State Approved

Yes